Posted by Michael Wonder on 02 Dec 2019
National Medical Products Administration approves Chipscreen Bioscience's chidamide (Epidaza) for breast cancer indication
29 November 2019 - Shenzhen Chipscreen Biosciences announced that the company's lead innovative product Epidaza (chidamide), an oral subtype-selective histone deacetylase inhibitor, previously approved for recurrent and refractory peripheral T cell lymphoma in China, has received approval for marketing application in its second indication from NMPA.
The indication includes chidamide combined with aromatase inhibitor in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with endocrine therapies for recurrence or progression.
